Clinical Trial Update: Evaluation of Dosing Interval of Higher Doses of Ranibizumab [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated dosing intervals for higher doses of ranibizumab in age-related macular degeneration and choroidal neovascularization and has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Brandon G. Busbee, MD | Conditions: Macular Degeneration, Choroidal Neovascularization | Phase 4 | Status: COMPLETED